MARKET

EVMN

EVMN

EVOMMUNE INC
NYSE
29.03
+12.04
+70.87%
Pre Market: 27.52 -1.51 -5.20% 04:04 02/11 EST
OPEN
29.52
PREV CLOSE
16.99
HIGH
33.20
LOW
21.80
VOLUME
464
TURNOVER
--
52 WEEK HIGH
33.20
52 WEEK LOW
13.89
MARKET CAP
915.14M
P/E (TTM)
-31.0481
1D
5D
1M
3M
1Y
5Y
1D
Evommune price target raised to $55 from $40 at Evercore ISI
TipRanks · 17h ago
Evommune: Robust IL-18 Phase 2a Atopic Dermatitis Data Underpins Buy Rating and Higher $55 Target with Additional Indication Upside
TipRanks · 17h ago
Evommune Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 18h ago
Evommune Price Target Raised to $65.00/Share From $35.00 by HC Wainwright & Co.
Dow Jones · 18h ago
HC Wainwright & Co. Maintains Buy on Evommune, Raises Price Target to $65
Benzinga · 18h ago
Evommune price target raised to $65 from $35 at H.C. Wainwright
TipRanks · 18h ago
Evommune's Stock Surges On Strong Results For New Eczema Drug
Benzinga · 19h ago
Midday Fly By: Coca-Cola reports Q4 beat, BP suspends buyback
TipRanks · 19h ago
More
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.

Webull offers Evommune, Inc. stock information, including NYSE: EVMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVMN stock methods without spending real money on the virtual paper trading platform.